

Una iniciativa de:



ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA



FUNDACIÓN
AEDV
PIEL SANA
ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA

Con el patrocinio de:



AEDV 35^a
edición

HIGHLIGHTS

Viena

30sep - 3oct
2026

AEDV 35ª edición

HIGHLIGHTS

Viena
30sep - 3oct
2026

**NO TENGO CONFLICTOS
DE INTERÉS**

Una iniciativa de:



Con el patrocinio de:



AEDV 35ª edición

HIGHLIGHTS

Viena
30sep - 3oct
2026

Psoriasis 1: Novedades clínicas y terapéuticas

Lucía Pinto Pulido


H. U. Príncipe de Asturias, Alcalá de Henares, Madrid

Una iniciativa de:





Con el patrocinio de:






IFN, interferon; IL, interleukin; TGF- β , transforming growth factor β ;
Th, T helper cell; T_{reg}, regulatory T cells.

Conrad C, presented at EADV 2022.




Unil



erythrodermic
Psoriasis



guttate
Psoriasis



unstable
Psoriasis



IFN-α:

- Ciclosporina
- UV




BII059 (*anti-BDCA2*)
MEDI7734 (*anti-ILT-7*)

IMO-8400 (*TLR7/9 inhibitor*)

Sifalimumab (*anti-IFNα*)
Anifrolumab (*anti-IFNAR*)

IFN-α + Th17:

- Inhibidores selectivos TYK2



The NEW ENGLAND
JOURNAL of MEDICINE



CURRENT ISSUE ▾ SPECIALTIES ▾

ORIGINAL ARTICLE


f X in t

Trial of Spesolimab for Generalized Pustular Psoriasis


¿Psoriasis pustulosa palmoplantar?



Results from a small pilot study with Spesolimab



Apremilast



Most biologic failures target the wrong pathway

Di Domizio J, Gilliet M, et al. J Eur Acad Dermatol Venereol 2026 — CHUV Lausanne

Approach

An 80-gene NanoString skin panel maps each biopsy onto reference immune modules (Th17, Th2, Th1, type I IFN, myeloid); a digital platform reports the dominant module and its matching targeted therapy.

Finding

In non-responders, 41% were misdiagnosed (eczema vs psoriasis), 30% had an immune shift (psoriasis resistant to anti-IL-17/IL-23 turning type I IFN-dominant) and 12% had paradoxical reactions.

Why it matters for this debate

A molecular test explains why a biologic failed and which one to use next, instead of switching by trial and error.

NON-RESPONDERS WITH A MODULE MISMATCH


82%

of 17 non-responders; only 17% had a matched profile, pointing to dosing or adherence

MISMATCHED PATIENTS AFTER SWITCHING

7 of 7 improved

after moving to the therapy matching their dominant module (retrospective, n=80, anti-Th2 or anti-Th17)



FUTURE: Stratification of patients based on clinical (phenotype) and molecular spectrum (endotype):

- Targeted biological therapy
- Targeted synthetic DMDs / conventional systemic therapy

PLENARY SESSION

Plenary lectures C

🕒 Saturday, 03 October • 12:00 - 13:00 CEST

Modelo de
predicción perfiles
moleculares en
tinción HE




The NEW ENGLAND JOURNAL of MEDICINE

Otoño 2025

ORIGINAL ARTICLE


Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents



- Psoriasis moderada-severa
- ≥12 años
- 200 mg/24h
- No monitorización lab

THE LANCET

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials



Aprobación FDA marzo 2026

BJD Sep 2026

Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials 

JAAD Oct 2026

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial

JEAD Sep 2026

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings


UPDATES


Late Breaking News

🕒 Friday, 02 October • 14:15 - 15:45 CEST


ORAL PRESENTATION

Long-term Durability and Safety of the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 2-year Findings From the ICONIC-TOTAL Randomized Controlled Trial





Allosteric TYK2 inhibitors bind to the regulatory site that is not conserved across JAKs, allowing for greater selectivity



- Oral/24h
- Sin monitorización laboratorio


UPDATES


Late Breaking News

🕒 Friday, 02 October • 14:15 - 15:45 CEST


ORAL PRESENTATION

Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates superior skin clearance (PASI 100) versus an approved oral TYK2 inhibitor, deucravacitinib, and a consistent safety profile in moderate-to-severe plaque psoriasis: results from a randomized phase 3 intraclass head-to-head trial (LATITUDE Atlas)






Conventional IgG
(~150 kDa)



Camelid antibody
(~95 kDa)


sdAb or nanobody
(~15 kDa)

Región variable de la
cadena pesada



Indicaciones en estudio:

- Hidradenitis suppurativa
- Pustulosis palmoplantar
- Artritis psoriásica y espondiloartritis axial



A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

ClinicalTrials.gov ID ⓘ NCT07013201

Sponsor ⓘ LEO Pharma

Information provided by ⓘ LEO Pharma (Responsible Party)


Last Update Posted ⓘ 2026-10-01

Recruiting ⓘ

[Find contact information](#)

[Check who can join](#)

Proof-of-concept
Phase 2a, Double-blind, 2-arm



DOI: 10.1111/exd.13414

ORIGINAL ARTICLE

WILEY Experimental Dermatology

Towards the development of a RNAi-based topical treatment for psoriasis: Proof-of-concept in a 3D psoriasis skin model

Eline Desmet¹ | Mireille Van Gele¹ | Lynda Grine¹ | Katrien Remaut² | Jo Lambert¹

RESEARCH ARTICLE

Open Access

CC BY


Transfersomes with core and surface-loaded NF-κB p65 siRNA for enhanced transdermal transfection and effective treatment of psoriasis

Hui Xing, Yuhui Yang, Ziyi Zhao, Kai Lv, Yiran Shao, Zhi Zhang, Dong Ma

First published: 14 April 2026 | <https://doi.org/10.1002/bmm2.70084>

VIEW METRICS

GUIDE · guselkumab · n = 880: treat early




Super response = completely clear (PASI 0) at weeks 20 and 28
Disease ≤ 2 years: **43.7% vs 28.1%** super-responders
After stopping: clear to week 116 in **43% vs 19%** (< 15 vs > 24 mo)

KNOCKOUT · hit hard, then stop

Risankizumab high dose – only 3 injections (W0, 4, 16), then stop · pilot, n = 20

Response after the last dose (weeks 28–100)



PASI 90: **94%** at week 28 → still **22%** at week 100
= 84 weeks without any injection · hypothesis-generating

Most patients need continuous therapy – but early, intensive treatment may reset the disease memory


Células T residentes memoria

BIOLOGICS AND IMMUNOTHERAPY · Volume 158, Issue 3, P857-871, September 2026 · Open Access


Epigenética

Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis: STEPIn mechanistic substudy results

Johann E. Gudjonsson, MD, PhD ^a · Katharina Bier, PhD ^b · Swann Gaulis, M Eng ^b · ... · Frank Kolbinger, Dr rer nat ^b · Felix Lohmann, PhD ^b · Curdin Conrad, MD ^g ... Show more



In **new-onset psoriasis**, differentially methylated CpG sites largely **normalize by week 16** (16 LS), whereas **long-standing psoriasis** skin exhibited **persistent DNA methylation changes** through **week 52** (52 LS) despite clinical clearance




THE LANCET *Regional Health Europe*

Agosto 2026

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial

- N= 244
- PASI ≤ 5 + DLQI ≤ 5 durante 6 meses
- Reducción dosis 50-67%
- Seguimiento 18 meses
- Brotes persistentes: No inferioridad (4% vs 1,6% IC -2%-6,8%)



- IL23 > IL 17
- Sin artritis psoriásica
- Menor PASI basal

BeNeBio cost-effectiveness Belgium EQ-5D

Variable	Mean	95% CI
Standard dose costs	€18,628.73	€17,882.95 – €19,307.01
Dose reduction costs	€12,625.18	€12,060.17 – €13,254.27
Incremental costs	- €6,003.54	- €6,657.47 – - €5,248.92
QALYs standard dose	1.31	1.19 – 1.4
QALYs dose reduction	1.3	1.18 – 1.37
Incremental QALYs	-0.02	- 0.07 – 0.04
iNMB	€5,073.64	€2,224.38 – €7,956.94

Dose reduction preserves essentially the same health benefit at substantially lower cost, resulting in a positive iNMB of €5,074 per patient.


Reducing long-term drug burden through personalised and precision management



PLAN-psoriasis feasibility trial



Study population:
94 adults with psoriasis
who have
clear/nearly clear skin
for ≥12 months on
risankizumab



NIHR | National Institute for Health and Care Research



Guy's and St Thomas'
NHS Foundation Trust



Ye et al, *BMJ Open* 2025



EADV Congress 2026
Vienna, Austria

Precision dosing at week 16

498

patients reduce dose
(13–24 weeks)

502

patients continue
standard dose

23%
less drug
exposure

18%
fewer injections

£2.3M
saved per year
per 1,000 pts

Nuevos
tratamientos
dirigidos

Medicina de
precisión: Perfiles
moleculares

Modificación de
enfermedad

Una iniciativa de:



ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA



ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA

Con el patrocinio de:



AEDV 35^a
edición

HIGHLIGHTS

Viena

30sep - 3oct
2026

La Academia Española de Dermatología y Venereología expresa su agradecimiento al patrocinador UCB, por su especial apoyo y contribución con la actividad formativa Highlights 2026.

Una iniciativa de:



ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA



ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLOGÍA

Con el patrocinio de:



AEDV 35ª
edición

HIGHLIGHTS

Viena

30sep - 3oct
2026

GRACIAS